Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objective of this study is to assess the efficacy and safety of an extended-release (ER) formulation of pramipexole in comparison with placebo for the treatment of fibromyalgia.
The objective of the open-label phase is to assess the safety profile and effect of Pramipexole (PPX) extended-release (ER) in fibromyalgia patients over a 24-week period.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Pramipexole ER | Experimental | 0.75 mg to 4.5 mg tablets of Pramipexole ER, once daily in the evening |
|
| Placebo | Placebo Comparator | Placebo tablets, once daily in the evening |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| pramipexole ER | Drug |
| ||
| placebo |
| Measure | Description | Time Frame |
|---|---|---|
| The Change in the Weekly Mean of the 24-hour Average Pain Score From a Daily Diary as Measured by the 11-point Likert Pain Scale | The 11-point Likert Pain Scale is a numerical rating scale completed by the patient that measures the intensity of pain. The intensity scores range from 0 (no pain) to 10 (worst possible pain) | Baseline and Week 29 |
| Measure | Description | Time Frame |
|---|---|---|
| The Proportion of Patients "Very Much Improved" or "Much Improved" on the Patient's Global Impression of Improvement (PGI-I) 7-point Scale | PGI-I is a self-reported scale completed by the patient that measures the degree of improvement at the time of assessment. The score ranges from 1 = very much improved to 7 = very much worse | Week 29 (at the end of the maintenance phase) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Boehringer Ingelheim | Boehringer Ingelheim | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| 248.637.01009 Boehringer Ingelheim Investigational Site | Birmingham | Alabama | United States | |||
| 248.637.01033 Boehringer Ingelheim Investigational Site |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Placebo | Patients receive placebo in dose up-titration steps |
| FG001 | Pramipexole | Patients receive pramipexole in dose up-titration steps |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
|
| The Short Form 36 (SF-36) Health Survey, Physical Functioning Subscale (Change From Baseline). | The SF-36 Health Survey is a self-administered 36-item instrument completed by the patient . SF 36 has subscales as follows: i) physical functioning (PF), ii) role limitations due to physical problems (RP), iii) bodily pain (BP), iv) general health perceptions (GH), v) vitality (VT), vi) social function (SF), vii) role limitations due to emotional problems (RE), viii) mental health (MH),ix)physical component summary (PCS)and x)mental component summary(MCS). Among the subscales, Physical functioning was key secondary endpoint while other were additional secondary endpoints. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale, with higher scores indicating better health status or functioning. The number of items per domain varies from 2 to 1 | Baseline and Week 29 |
| The Proportion of Patients With at Least a 30% or at Least a 50% Improvement Relative to Baseline in Pain (Assessed on the 11-point Likert Pain Scale | 11-Point Likert Pain Scale is a numerical rating scale completed by the patient that measures the intensity of pain. The intensity scores range from: 0 = no pain to 10 = worst possible pain . | Baseline and Week 29 |
| Fibromyalgia Impact Questionnaire (FIQ) Total Score (Change From Baseline) | FIQ is a self-reported scale completed by the patient that measures patient status, progress, and outcomes over the past week. The FIQ is composed of a total of 20 items; the first 11 items measure physical functioning, and each item is rated on a four-point Likert scale. Items 12 and 13 measure the number of days the patient felt well and the number of days the patient felt unable to work due to their fibromyalgia symptoms. Items 14 through 20 are numerical, 11-point Likert scales (marked in 10-point increments) on which the patient rates work difficulty, pain, fatigue, morning tiredness, stiffness, anxiety, and depression. The total score ranges from 0 to 80. A higher score indicates a more negative impact | Baseline and Week 29 |
| Hospital Anxiety and Depression Scale (HADS) (Change From Baseline). | The Hospital Anxiety and Depression Scale (HADS) measures the severity of anxiety and depression. The severity score ranges from: 0 = least severe to 3 = most severe. The total score ranges from 0 to 21; the higher the score, the more severe the anxious/depressive symptoms | Baseline and Week 29 |
| The Short Form 36 (SF-36) Health Survey (Change From Baseline) (Excluding the Physical Functioning Subscale(PF)). | The SF-36 Health Survey is a self-administered 36-item instrument completed by the patient . SF 36 has subscales as follows: i) physical functioning (PF), ii) role limitations due to physical problems (RP), iii) bodily pain (BP), iv) general health perceptions (GH), v) vitality (VT), vi) social function (SF), vii) role limitations due to emotional problems (RE), viii) mental health (MH),ix)physical component summary (PCS)and x)mental component summary(MCS). Among the subscales, Physical functioning was key secondary endpoint while other were additional secondary endpoints. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale, with higher scores indicating better health status or functioning. The number of items per domain varies from 2 to 1 | Baseline and Week 29 |
| Euroqol- 5 Dimensions (EQ-5D) Survey (Change From Baseline) | The Euroqol- 5 Dimension (EQ-5D) Health Survey is a generic, multidimensional, health related, quality-of-life instrument that contains two parts-a health status profile and a visual analog scale (VAS) to rate global health-related quality of life. The profile contains five items corresponding to five health domains- mobility, self-care, usual activities, pain/discomfort, and mood. A single score is generated for each health state. Data from the EQ-5D can be converted into 243 unique health states. For each health state, there exists a corresponding valuation that allows the patient's health to be represented as an index, which is a value between -0.594 and 1; the higher the score, the better the quality of life. | Baseline and Week 29 |
| Multidimensional Assessment of Fatigue (MAF) Index (Change From Baseline) | The Multidimensional Assessment of Fatigue (MAF) Index is a 16-item, self-reporting instrument designed to collect data on four dimensions of fatigue- severity, distress, degree of interference in activities of daily living, and timing . | Baseline and Week 29 |
| Medical Outcomes Study (MOS) Sleep Scale (Change From Baseline) | The Medical Outcomes Study (MOS) sleep scale is a 12-item (MOS1 to MOS12) self reporting sleep measure. | Baseline and Week 29 |
| Clinical Global Impression of Severity (CGI-S Scores) | Clinical Global Impression of Severity (CGI-S) Scale is a clinician's assessment of patient's severity of illness. The score ranges from 1 = normal, not at all ill to 7 = among the most extremely ill patients | Baseline and Week 29 |
| Frequency of Rescue Medication for Pain | Acetaminophen/paracetamol (maximum of 4 g/day) to be allowed as rescue medication for pain. | Week 29 |
| Change From Baseline in Mean Tender Point Threshold | The Tender Point Pain Threshold will be assessed for all 18 tender points by a study clinician. A dolorimeter will be used to exert the pressure at each point and to measure the threshold reading; when the patient first indicates pain, the threshold will be recorded in kg/sq.cm ;If the patient reports pain before 1.0 kg/sq.cm is reached (>0 kg/sq.cm), 1.0 kg/sq.cm will be entered. If the patient does not report pain when the maximum pressure is applied (10.0 kg/sq.cm),0 (no pain) will be entered. | Baseline and Week 29 |
| Phoenix |
| Arizona |
| United States |
| 248.637.01045 Boehringer Ingelheim Investigational Site | Tucson | Arizona | United States |
| 248.637.01034 Boehringer Ingelheim Investigational Site | Hot Springs | Arkansas | United States |
| 248.637.01032 Boehringer Ingelheim Investigational Site | Arcadia | California | United States |
| 248.637.01044 Boehringer Ingelheim Investigational Site | Los Angeles | California | United States |
| 248.637.01036 Boehringer Ingelheim Investigational Site | Santa Ana | California | United States |
| 248.637.01042 Boehringer Ingelheim Investigational Site | Englewood | Colorado | United States |
| 248.637.01031 Boehringer Ingelheim Investigational Site | Danbury | Connecticut | United States |
| 248.637.01035 Boehringer Ingelheim Investigational Site | DeLand | Florida | United States |
| 248.637.01023 Boehringer Ingelheim Investigational Site | Fort Myers | Florida | United States |
| 248.637.01047 Boehringer Ingelheim Investigational Site | Orlando | Florida | United States |
| 248.637.01043 Boehringer Ingelheim Investigational Site | Palm Beach Gardens | Florida | United States |
| 248.637.01040 Boehringer Ingelheim Investigational Site | Sunrise | Florida | United States |
| 248.637.01027 Boehringer Ingelheim Investigational Site | Tampa | Florida | United States |
| 248.637.01007 Boehringer Ingelheim Investigational Site | Atlanta | Georgia | United States |
| 248.637.01028 Boehringer Ingelheim Investigational Site | Chicago | Illinois | United States |
| 248.637.01010 Boehringer Ingelheim Investigational Site | Lexington | Kentucky | United States |
| 248.637.01016 Boehringer Ingelheim Investigational Site | Newton | Massachusetts | United States |
| 248.637.01014 Boehringer Ingelheim Investigational Site | Lansing | Michigan | United States |
| 248.637.01020 Boehringer Ingelheim Investigational Site | Flowood | Mississippi | United States |
| 248.637.01018 Boehringer Ingelheim Investigational Site | Picayune | Mississippi | United States |
| 248.637.01012 Boehringer Ingelheim Investigational Site | Kansas City | Missouri | United States |
| 248.637.01017 Boehringer Ingelheim Investigational Site | Billings | Montana | United States |
| 248.637.01024 Boehringer Ingelheim Investigational Site | Albuquerque | New Mexico | United States |
| 248.637.01008 Boehringer Ingelheim Investigational Site | Albany | New York | United States |
| 248.637.01002 Boehringer Ingelheim Investigational Site | New York | New York | United States |
| 248.637.01025 Boehringer Ingelheim Investigational Site | Charlotte | North Carolina | United States |
| 248.637.01026 Boehringer Ingelheim Investigational Site | Fargo | North Dakota | United States |
| 248.637.01004 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | United States |
| 248.637.01038 Boehringer Ingelheim Investigational Site | Columbus | Ohio | United States |
| 248.637.01003 Boehringer Ingelheim Investigational Site | Oklahoma City | Oklahoma | United States |
| 248.637.01046 Boehringer Ingelheim Investigational Site | Medford | Oregon | United States |
| 248.637.01006 Boehringer Ingelheim Investigational Site | Portland | Oregon | United States |
| 248.637.01039 Boehringer Ingelheim Investigational Site | Duncansville | Pennsylvania | United States |
| 248.637.01015 Boehringer Ingelheim Investigational Site | Warwick | Rhode Island | United States |
| 248.637.01019 Boehringer Ingelheim Investigational Site | Austin | Texas | United States |
| 248.637.01037 Boehringer Ingelheim Investigational Site | San Antonio | Texas | United States |
| 248.637.01041 Boehringer Ingelheim Investigational Site | Salt Lake City | Utah | United States |
| 248.637.01021 Boehringer Ingelheim Investigational Site | Renton | Washington | United States |
| 248.637.01029 Boehringer Ingelheim Investigational Site | Seattle | Washington | United States |
| 248.637.01011 Boehringer Ingelheim Investigational Site | Spokane | Washington | United States |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Treated Set, All patients randomized and received treatment
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Placebo | Patients receiving matching placebo |
| BG001 | Pramipexole | Patients receiving pramipexole |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | The Change in the Weekly Mean of the 24-hour Average Pain Score From a Daily Diary as Measured by the 11-point Likert Pain Scale | The 11-point Likert Pain Scale is a numerical rating scale completed by the patient that measures the intensity of pain. The intensity scores range from 0 (no pain) to 10 (worst possible pain) | FAS (All randomized and treated patients with a baseline and at least one post-baseline will be included in the Full Analysis Set (FAS)) | Posted | Baseline and Week 29 |
|
| ||||||||||||||||||||||
| Secondary | The Proportion of Patients "Very Much Improved" or "Much Improved" on the Patient's Global Impression of Improvement (PGI-I) 7-point Scale | PGI-I is a self-reported scale completed by the patient that measures the degree of improvement at the time of assessment. The score ranges from 1 = very much improved to 7 = very much worse | FAS (All randomized and treated patients with a baseline and at least one post-baseline will be included in the Full Analysis Set (FAS)) | Posted | Week 29 (at the end of the maintenance phase) |
|
| ||||||||||||||||||||||
| Secondary | The Short Form 36 (SF-36) Health Survey, Physical Functioning Subscale (Change From Baseline). | The SF-36 Health Survey is a self-administered 36-item instrument completed by the patient . SF 36 has subscales as follows: i) physical functioning (PF), ii) role limitations due to physical problems (RP), iii) bodily pain (BP), iv) general health perceptions (GH), v) vitality (VT), vi) social function (SF), vii) role limitations due to emotional problems (RE), viii) mental health (MH),ix)physical component summary (PCS)and x)mental component summary(MCS). Among the subscales, Physical functioning was key secondary endpoint while other were additional secondary endpoints. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale, with higher scores indicating better health status or functioning. The number of items per domain varies from 2 to 1 | FAS (All randomized and treated patients with a baseline and at least one post-baseline will be included in the Full Analysis Set (FAS)) | Posted | Baseline and Week 29 |
| |||||||||||||||||||||||
| Secondary | The Proportion of Patients With at Least a 30% or at Least a 50% Improvement Relative to Baseline in Pain (Assessed on the 11-point Likert Pain Scale | 11-Point Likert Pain Scale is a numerical rating scale completed by the patient that measures the intensity of pain. The intensity scores range from: 0 = no pain to 10 = worst possible pain . | FAS (All randomized and treated patients with a baseline and at least one post-baseline will be included in the Full Analysis Set (FAS)) | Posted | Baseline and Week 29 |
|
| ||||||||||||||||||||||
| Secondary | Fibromyalgia Impact Questionnaire (FIQ) Total Score (Change From Baseline) | FIQ is a self-reported scale completed by the patient that measures patient status, progress, and outcomes over the past week. The FIQ is composed of a total of 20 items; the first 11 items measure physical functioning, and each item is rated on a four-point Likert scale. Items 12 and 13 measure the number of days the patient felt well and the number of days the patient felt unable to work due to their fibromyalgia symptoms. Items 14 through 20 are numerical, 11-point Likert scales (marked in 10-point increments) on which the patient rates work difficulty, pain, fatigue, morning tiredness, stiffness, anxiety, and depression. The total score ranges from 0 to 80. A higher score indicates a more negative impact | FAS (All randomized and treated patients with a baseline and at least one post-baseline will be included in the Full Analysis Set (FAS)) | Posted | Baseline and Week 29 |
|
| ||||||||||||||||||||||
| Secondary | Hospital Anxiety and Depression Scale (HADS) (Change From Baseline). | The Hospital Anxiety and Depression Scale (HADS) measures the severity of anxiety and depression. The severity score ranges from: 0 = least severe to 3 = most severe. The total score ranges from 0 to 21; the higher the score, the more severe the anxious/depressive symptoms | FAS (All randomized and treated patients with a baseline and at least one post-baseline will be included in the Full Analysis Set (FAS)) | Posted | Baseline and Week 29 |
|
| ||||||||||||||||||||||
| Secondary | The Short Form 36 (SF-36) Health Survey (Change From Baseline) (Excluding the Physical Functioning Subscale(PF)). | The SF-36 Health Survey is a self-administered 36-item instrument completed by the patient . SF 36 has subscales as follows: i) physical functioning (PF), ii) role limitations due to physical problems (RP), iii) bodily pain (BP), iv) general health perceptions (GH), v) vitality (VT), vi) social function (SF), vii) role limitations due to emotional problems (RE), viii) mental health (MH),ix)physical component summary (PCS)and x)mental component summary(MCS). Among the subscales, Physical functioning was key secondary endpoint while other were additional secondary endpoints. Each domain is scored by summing the individual items and transforming the scores into a 0 to 100 scale, with higher scores indicating better health status or functioning. The number of items per domain varies from 2 to 1 | FAS (All randomized and treated patients with a baseline and at least one post-baseline will be included in the Full Analysis Set (FAS)) | Posted | Baseline and Week 29 |
| |||||||||||||||||||||||
| Secondary | Euroqol- 5 Dimensions (EQ-5D) Survey (Change From Baseline) | The Euroqol- 5 Dimension (EQ-5D) Health Survey is a generic, multidimensional, health related, quality-of-life instrument that contains two parts-a health status profile and a visual analog scale (VAS) to rate global health-related quality of life. The profile contains five items corresponding to five health domains- mobility, self-care, usual activities, pain/discomfort, and mood. A single score is generated for each health state. Data from the EQ-5D can be converted into 243 unique health states. For each health state, there exists a corresponding valuation that allows the patient's health to be represented as an index, which is a value between -0.594 and 1; the higher the score, the better the quality of life. | FAS (All randomized and treated patients with a baseline and at least one post-baseline will be included in the Full Analysis Set (FAS)) | Posted | Baseline and Week 29 |
|
| ||||||||||||||||||||||
| Secondary | Multidimensional Assessment of Fatigue (MAF) Index (Change From Baseline) | The Multidimensional Assessment of Fatigue (MAF) Index is a 16-item, self-reporting instrument designed to collect data on four dimensions of fatigue- severity, distress, degree of interference in activities of daily living, and timing . | FAS (All randomized and treated patients with a baseline and at least one post-baseline will be included in the Full Analysis Set (FAS)) | Posted | Baseline and Week 29 |
|
| ||||||||||||||||||||||
| Secondary | Medical Outcomes Study (MOS) Sleep Scale (Change From Baseline) | The Medical Outcomes Study (MOS) sleep scale is a 12-item (MOS1 to MOS12) self reporting sleep measure. | FAS (All randomized and treated patients with a baseline and at least one post-baseline will be included in the Full Analysis Set (FAS)) | Posted | Baseline and Week 29 |
|
| ||||||||||||||||||||||
| Secondary | Clinical Global Impression of Severity (CGI-S Scores) | Clinical Global Impression of Severity (CGI-S) Scale is a clinician's assessment of patient's severity of illness. The score ranges from 1 = normal, not at all ill to 7 = among the most extremely ill patients | FAS (All randomized and treated patients with a baseline and at least one post-baseline will be included in the Full Analysis Set (FAS)) | Posted | Baseline and Week 29 |
|
| ||||||||||||||||||||||
| Secondary | Frequency of Rescue Medication for Pain | Acetaminophen/paracetamol (maximum of 4 g/day) to be allowed as rescue medication for pain. | FAS (All randomized and treated patients with a baseline and at least one post-baseline will be included in the Full Analysis Set (FAS)) | Posted | Week 29 |
|
| ||||||||||||||||||||||
| Secondary | Change From Baseline in Mean Tender Point Threshold | The Tender Point Pain Threshold will be assessed for all 18 tender points by a study clinician. A dolorimeter will be used to exert the pressure at each point and to measure the threshold reading; when the patient first indicates pain, the threshold will be recorded in kg/sq.cm ;If the patient reports pain before 1.0 kg/sq.cm is reached (>0 kg/sq.cm), 1.0 kg/sq.cm will be entered. If the patient does not report pain when the maximum pressure is applied (10.0 kg/sq.cm),0 (no pain) will be entered. | FAS (All randomized and treated patients with a baseline and at least one post-baseline will be included in the Full Analysis Set (FAS)) | Posted | Baseline and Week 29 |
|
|
Up to 72 days
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Placebo | 1 | 31 | 10 | 31 | |||
| EG001 | Pramipexole | 0 | 30 | 18 | 30 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Iron deficiency anaemia | Blood and lymphatic system disorders | MedDRA 11.1 | Systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| insomnia | Psychiatric disorders | MedDRA 11.1 | Systematic Assessment |
| |
| sleep attacks | Psychiatric disorders | MedDRA 11.1 | Systematic Assessment |
| |
| somnolence | Nervous system disorders | MedDRA 11.1 | Systematic Assessment |
| |
| dizziness | Nervous system disorders | MedDRA 11.1 | Systematic Assessment |
| |
| headache | Nervous system disorders | MedDRA 11.1 | Systematic Assessment |
| |
| nausea | Gastrointestinal disorders | MedDRA 11.1 | Systematic Assessment |
| |
| dry mouth | Gastrointestinal disorders | MedDRA 11.1 | Systematic Assessment |
| |
| Gastrooesophageal disease | Gastrointestinal disorders | MedDRA 11.1 | Systematic Assessment |
| |
| hyperhidrosis | Skin and subcutaneous tissue disorders | MedDRA 11.1 | Systematic Assessment |
| |
| rash | Skin and subcutaneous tissue disorders | MedDRA 11.1 | Systematic Assessment |
| |
| arthralgia | Musculoskeletal and connective tissue disorders | MedDRA 11.1 | Systematic Assessment |
| |
| fatigue | General disorders | MedDRA 11.1 | Systematic Assessment |
| |
| Diarrhoea | Gastrointestinal disorders | MedDRA 11.1 | Systematic Assessment |
|
Early termination leading to no number of subjects analysed for any outcome measure
Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals | Boehringer Ingelheim Pharmaceuticals | 1-800-243-0127 | clintriage.rdg@boehringer-ingelheim.com |
| ID | Term |
|---|---|
| D005356 | Fibromyalgia |
| ID | Term |
|---|---|
| D009135 | Muscular Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
| D009468 | Neuromuscular Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
| Male |
|
| Units |
|---|
| Counts |
|---|
| Participants |
|
| Participants |
|
| Units | Counts |
|---|
| Participants |
|
| Participants |
|